托珠单抗治疗 HIV 合并重症 COVID-19 患者：病例报告。
Tocilizumab in HIV patient with severe COVID-19: case report.
机构信息
Advanced Research Center in Medicine, Uniao das Faculdades dos Grandes Lagos-UNILAGO, Emilia Tarraf st., 340, São Jose do Rio Preto, SP, 15055-460, Brazil.
Advanced Research Center in Medicine, Uniao das Faculdades dos Grandes Lagos, UNILAGO, São Jose do Rio Preto, SP, Brazil.
出版信息
AIDS Res Ther. 2021 Oct 16;18(1):73. doi: 10.1186/s12981-021-00404-5.
BACKGROUND
A 73-year-old male patient who had a history of Human Immunodeficiency Virus (HIV) infection for over 20 years was diagnosed with SARS-CoV-2 infection.
CASE PRESENTATION
The patient was admitted to the Intensive Care Unit (ICU), where he remained for 25 days, due to a severe condition. Intubation, hemodialysis, and tracheostomy were necessary to maintain homeostasis. In addition to regular treatment with etravirine, dolutegravir, darunavir, and ritonavir for highly active antiretroviral therapy, the patient received tocilizumab, which showed a great recovery in the patient's condition.
CONCLUSION
The patient had several risk factors, such as male gender, age > 70 years, and arterial hypertension. The use of tocilizumab was of great importance in the patient's recovery since the drug increased his immune response, which is deficient, due to HIV infection.
背景
一位 73 岁的男性患者 HIV 感染病史超过 20 年，被诊断为感染 SARS-CoV-2。
病例介绍
患者因病情严重而被收住重症监护病房（ICU），共 25 天。为了维持内环境稳定，他接受了气管插管、血液透析和气管切开术。除了使用依曲韦林、多替拉韦、达芦那韦和利托那韦进行高效抗逆转录病毒治疗外，患者还接受了托珠单抗治疗，这使他的病情有了很大的恢复。
结论
患者有多种危险因素，如男性、年龄>70 岁和动脉高血压。托珠单抗的使用对患者的恢复非常重要，因为该药物增加了他因 HIV 感染而缺乏的免疫反应。
Zotero 插件